Number of patients: 223
Follow up: 24-month
Type of lesion: de novo coronary lesions
In conclusion, this first randomized trial with a novel thin-strut, cobalt-chromium SES with a durable fluoro-acrylate-based biostable polymer found it to be non-inferior to the gold standard second generation EES in terms of angiographic parameters of restenosis. From the clinical point of view, the number of events at 2 years was very low in both groups, reflecting good clinical performance of angiolite.
angiolite is among the best of the new DES generation
This trial demonstrates similar anti-restenotic efficacy at mid-term follow-up of the Angiolite®SES vs. EES. Clinical endpoints were comparable between groups at 2-year follow-up.
Dr J. Moreu Burgos – Hospital Virgen de la Salud (Toledo, SPA)